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Abstract
Introduction: The search for new compounds with antihypoxic and cardioprotective effects among 3-oxypyridine 
derivatives is promising.
Research objectives: To study the anti-hypoxic and cardioprotective effects of 3-oxypyridine derivatives.
Materials and methods: The search for compounds with an antihypoxic effect was carried out on blood leukocytes of 
rats in in vitro. To simulate hypoxia, Oil for Tissue Culture (SAGE) was used, 500 µl of which was applied into wells 
over a growth medium in order to block gas exchange. The cardioprotective effect of 3-oxypyridine derivatives was 
studied in the model of coronary-occlusive myocardial infarction (30 minutes of ischemia, 90 minutes of reperfusion). 
The level of troponin I (Tn I) was determined as a biochemical marker of myocardial damage.
Results and discussion: In the in vitro experiments, when culting white blood cells, the lead compound in the group 
of 3-oxypyridine derivatives was identified under code LKhT 21–16, which increases the number of viable cells in the 
presence of hypoxia, surpassing the reference drugs. When confirming the chemical structure of the lead compound, 
LHT 21–16, a high sensitivity of the NMR spectroscopy method was revealed.
In studying the cardioprotective activity in the model of coronary-occlusive myocardial infarction compound LHT 
21–16 exerted a marked cardioprotective effect when reducing the size of the necrotic zone and the level of biochemical 
marker Tn I.
Conclusions: 3-oxypiridine derivatives have antihypoxic and cardioprotective effects, which shows in a high number 
of surviving cells in the presence of hypoxia in the in vitro model, a reduced size of the necrotic zone and a reduced 
level of Tn I in the coronary-occlusive myocardial infarction.
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Introduction
In recent years, the role of free radical oxidation in the 
normal and pathological conditions has been given consi-
derable attention to (Pająk et al. 2017). Free radicals are 
formed in the body as a result of the metabolism of oxygen 
dissolved in tissues, and reactive oxygen species (ROSs) 
formed thereby cause oxidation of membrane lipids, pro-
teins, polysaccharides, and nucleic acids (Yakusheva et 
al. 2018). The damaging effect of free radicals is opposed 
by a multilevel endogenous antioxidant system, which 
balances the free radical oxidation and antioxidant sys-
tems (Chanchaeva et al. 2013). Intensive formation of 
ROS and insufficient activity of the antioxidant system 
lead to a condition, accompanied by intensified destruc-
tive processes in tissues which go along with oxidative 
stress (Bayburina et al. 2017). This condition is involved 
in the pathogenesis of a significant number of diseases 
(Tyurenkov et al. 2013). In case of oxidative stress, the 
use of exogenous antioxidants as agents for pharmacolo-
gical correction of free radical oxidation is pathogeneti-
cally substantiated (Godunova et al. 2018).
Drugs of different chemical nature are widely used for 
pharmacological correction of oxidative stress (Karneev 
2007). The chemical structure of a substance determines 
its targets of action in correcting oxidative stress (Smirno-
va et al. 2014). Accordingly, taking this relationship into 
account may be useful when searching for new groups of 
drugs for correcting oxidative stress. From the chemical 
point of view, the prerequisites for high efficiency of the 
compound as an antioxidant are the presence of an aro-
matic or heteroaromatic cycle of low molecular weight; 
the presence of one hydroxyl group in the aromatic cycle 
or a side chain to provide lipophilicity and antiradical ac-
tivity; good solubility in the medium where free radicals 
are generated (hydrophilicity); the presence of saturated 
or unsaturated alkyl chain in the aromatic cycle as a pre-
requisite for the integration of the compound into the cell 
membrane (Štěrba et al. 2013, Blinov et al. 2012).
3-oxypiridine derivatives which in the experimental 
and clinical studies have shown the antioxidant effica-
cy have the above properties (Yasnetsov and Smirnov 
2005). A wide range of pharmacological activity and low 
toxicity determine the relevance of the search for and de-
velopment of new original drugs in the group of synthet-
ic pyridine derivatives (Smirnov et al. 1985, Yasnetsov 
et al. 2017).
Materials and methods
In the first stage, an in vitro analysis of antihypoxic effect 
among 3-hydroxypyridine derivatives (17 compounds) 
was performed. The experiment was carried out on the 
fraction of leukocytes obtained by the conventional me-
thod (Frimmel 1987).
The leukocyte suspension was washed using centrif-
ugation at 1000 rpm for 10 min; the supernatant was 
removed, and the residue was resuspended in 12 ml of 
growth medium RPMI-1640 with glutamine (PanEco, 
Russia). Cultivation was carried out in 24-well plastic 
plates (SPL Life Sciences Co., Ltd, Korea).
The wells with cells in an intact growth medium RPMI-
1640 with glutamine (PanEco, Russia) were a group of 
positive control, a 5% DMSO solution (PanEco, Russia) 
in a growth medium RPMI-1640 with glutamine (PanEco, 
Russia) was used as a negative control.
To simulate hypoxia in the in vitro experiments, oil 
was added over the growth medium to stop oxygen sup-
ply. Into each well of the plate, 500 µl of growth medi-
um containing leukocytes was added and 500 µl of Oil 
for Tissue Culture (SAGE, USA) was applied over the 
growth medium.
Trimetazidine (Sigma-Aldrich, USA) and Ethylmeth-
ylhydroxypyridine succinate (Mexidol, PHARMASOFT, 
Russia) at a dose of 1 mmol/L as a reference drug, recom-
mended by the Ministry of health of the Russian Federa-
tion and the Federal Medical and Biological Agency for 
biomedical (preclinical) study of antihypoxic activity of 
drugs (Karkishchenko et al. 2017), were selected.
Cultivation of white blood cells was carried out in a 
CO2 incubator filled with a gas mixture (95% air + 5% 
CO2) at a temperature of 37°C and a relative humidity of 
100% during 6 hours. To assess the viability of the cells, 
a two-component dye comprising 2µМ of calcein (Sig-
ma-Aldrich, USA) and 4µМ of ethidium bromide (Sig-
ma-Aldrich, USA) (Bozena et al. 2001) was used.
The growth medium was drained from the wells of the 
plate, the cells were washed with Hanks solution (PanE-
co, Russia); after which 200 µl of Hanks solution (PanE-
co, Russia) and 100 µl of solution containing a two-com-
ponent fluorescent dye were added to the cells remaining 
at the bottom of the wells. The cells were cultured in a 
CO2 incubator (CO2 5%) for 45 minutes at a temperature 
of 37° C, after which the leukocytes were washed with 
Hanks solution (PanEco, Russia). 
Viability was assessed using a fluorescent microscope 
Eclipse Ti-S (Nikon, Japan) under x10 magnification. Flu-
orescence of living cells was recorded at a wavelength of 
495 nm, that of dead cells – at a wavelength of 635 nm. 
To calculate the number of cells, the program EZ-C1 
FreeViewer software (Version 3.90, Nikon, Japan) was 
used. Each experimental group consisted of 12 wells, in 
each of which 3 random fields of view were photographed 
and calculated. In total, more than 40 thousand cells were 
counted in the experiment. Cell viability was calculated 
using the formula: number of living cells/(number of living 
cells+number of dead cells) × 100 (Lightfoot et al. 2007). 
The second stage of the study confirmed the structure 
of the lead compound by the physico-chemical NMR 
method, in order to prove the presence and place of the 
privileged chemical groups, which is especially important 
for the lead compounds selected for an in-depth study of 
the pharmacological properties. The 1H NMR spectra were 
measured using the Agilent MR400+ spectrometer in DM-
SO-D6 solutions, using the σ-chemical shift scale (ppm).
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At the third stage, the cardioprotective activity was 
syidied in the model of coronary-occlusive myocardial 
infarction.
The simulation of coronary-occlusive myocardial in-
farction was carried out in rabbits sensu Kogan A.Kh. 
(Kogan and Tetelbaum 1979). The experimental proto-
col included 30 minutes of ischemia and 90 minutes of 
reperfusion. Twenty minutes before the coronary artery 
ligation, the studied compound was injected into the mar-
ginal vein of the rabbit’s ear. Troponin I (Tn) was selected 
to evaluate biochemical markers of myocardial infarc-
tion. Blood sampling for its determination was performed 
from the right ventricle into a toss-away vacuum tube 
with an anticoagulant. Its concentration in plasma was 
determined 2 hours later, using the immunofluorescence 
device Triage MeterPro (Biosite, USA). The size of the 
necrotic zone was determined using the weight planim-
etry method.
All the experiments were performed in compliance 
with The European Convention for the Protection of Ver-
tebrate Animals Used for Experimental and Other Scien-
tific Purposes [Derective 2010/63/EU].
The statistical analysis was carried out with the help of 
StatSoft STATISTICA 6.0 software.
Results and discussion
At the screening stage, statistically significant differences 
were found between the negative control group (hypoxia) 
when compared to the positive control group, the nega-
tive control group (DMSO), with the groups containing 
reference drugs and the experimental group containing 
a 3-oxypyride derivative under the laboratory code LHT 
21–16 (Var22). All other experimental groups containing 
3-oxypyridine derivatives (LHT Var6 – Var21) did not 
show any significant differences from the group of ne-
gative control (hypoxia), which indicates the absence of 
antihypoxic effect (Figure 1).
The study found that the new derivative of 3-oxypyri-
dine under the laboratory code LHT 21–16 (cell viability 
81.40±3.19%, p<0.01) has a more pronounced antihy-
poxic effect compared with the reference drugs (trimetha-
zidine – 73.72±7.25%, p<0.01; Mexidol – 63.18±2.87%, 
p<0.01), which is manifested in a significant increase in 
the percentage of the viable cells compared with the nega-
tive control in hypoxia (38.98±5.61%).
The cell viability in the presence of hypoxia with 
the addition of LHT 21–16 had no significant differ-
ences in comparison with the group of positive control 
(79.52±3.71%), which proves a high antihypoxic effect 
of this compound. So, in vitro the protective antihypoxic 
effect of LHT 21–16 exceeds that of the reference drugs 
Trimetazidine and Mexidol.
At the second stage of the study, the structure of the 
lead compound LHT 21–16 was confirmed. Figure 4 
shows the 1H NMR spectrum for LHT 21–16. In the 1H 
NMR spectrum of the compound LHT 21–16, the proton 
signals of the methyl and ethyl groups of 2-ethyl substit-
uent of 2-ethyl-6-methyl-3-hydroxypyridine are shown in 
the form of a triplet with integral intensity of three pro-
tons and a quartet with integral intensity of two protons 
with chemical shifts and the spin-spin splitting constants, 
1.11 (t, J = 7.5 Hz, 3H) and 2.63 (q, J = 7.5 Hz, 2H), re-
spectively. The proton signals of the pyridine nucleus are 
manifested as two doublets 6.99 (d, J = 8.1 Hz, 1H), 6.84 
(d, J = 8.1 Hz, 1H). The singlet of the proton of the hy-
droxyl group at position 3 of the pyridine nucleus is suffi-
ciently broadened and can be poorly seen on the panoram-
ic spectrum, but it clearly manifests itself in the analysis 
of integral intensities at 10 ppm. The proton signals of the 
pyridine nucleus of nicotinic acid appear in the region of 
Figure 1. Results of in vitro screening in the group of 3 – oxypyridine derivatives. Var1 – positive control, Var2 – negative control 
(DMSO), Var3 – negative control (hypoxia), Var 4 – trimethazidine; Var5 – Mexidol; Var6 – Var22 – 3-oxypyridine derivatives 
(LHT). * – p<0.01
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aromatic protons in the form of a singlet corresponding to 
the proton signal at position 2, two doublets correspond-
ing to proton signals at positions 4 and 6, and a triplet of 
one proton at position 5, 8.78–8.74 (m, 1H), 8.25 (dt, J = 
7.9, 1.9Hz, 1H), 7.52 (dd, J = 7.9, 4.8Hz, 1H).
Thus, the method proposed for identifying the com-
pound of LHT 21–16 showed high sensitivity necessary 
to provide incoming control of the test lead compound.
In a number of experiments, the ability of Mexidol, 
3-hydroxypyridine derivative, to reduce the size of the 
necrotic zone in the model of coronary-occlusive myo-
cardial infarction (Mikhin et al. 2016, Danilenko and 
Pokrovskii 2014), therefore, it can be assumed that the 
lead compound LHT 21–16, has the similar properties. 
The ligation of the left anterior descending artery in 
rabbits in the control group of animals resulted in myo-
cardial necrosis, the size of which was 46.03±13.1%. The 
administration of Mexidol at a dose of 85.72 mg/kg and 
LHT 21–16 at a dose of 52 mg/kg resulted in a statistical-
Figure 2. Fluorescence of live (green) and dead (red) leukocytes. A – hypoxia simulation (negative control); B – in the presence of 
the lead compounds from the group of 3-oxypyridine derivatives under laboratory code LHT 21-16. ×10 zoom
A
B
Figure 3. Сhemical formula LHT 21–16
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Figure 4. The 1H-NMR spectrum of compound LHT 21–16.
 
1.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.010.5
f1 (мд)
0
50
100
150
200
250
300
350
400
450
lht21-16
Gradient Shimming
3.
00
3.
00
2.
05
1.
06
1.
05
1.
02
1.
01
0.
99
1.
00
1.
03
A (d)
6.84
B (d)
6.99
C (dt)
8.25
D (m)
8.76
E (dd)
7.52
F (t)
1.11
G (q)
2.63
H (q)
2.63
1.
09
1.
11
1.
13
2.
29
2.
60
2.
62
2.
64
2.
66
6.
83
6.
85
6.
98
7.
00
7.
50
7.
51
7.
52
7.
53
8.
23
8.
24
8.
25
8.
26
8.
76
8.
77
9.
05
9.
57
129
ly significant reduction of the necrotic zone compared to 
that in the control group of animals.
In all the animals during ischemia/reperfusion of the 
left coronary artery (“control-ischemia/reperfusion”, 
“ischemia/reperfusion+Mexidol 85.72 mg/kg”, “ische-
mia/reperfusion+LHT-21-16 52 mg/kg”), ischemic myo-
cardial damage was observed. In the animals, to which 20 
minutes before ischemia comparison drug Mexidol 85.72 
mg/kg had been intravenously administered, the ischemic 
zone was 31.2±4.1% (Table 1).
The lead compound LHT 21–16 (52 mg/kg) signifi-
cantly reduces the necrotic zone to 26.2±2.7%, whereas 
in the control group it was 46.3±5.1%.
In an immunoenzyme analysis of myocardial damage 
in the control group of animals, the level of Tn I in blood 
plasma was 16.6±2.4 ng/ml, which is 4.8 times higher 
than that in the sham operated animals.
Reference drug Mexidol reduced the level of Tn I 1.4 
times in comparison with the control group. All the ani-
mals who had been administered substance LHT 21–16 
showed a 2.2-time decrease in the level of Tn I compared 
with the control group (p<0.05) and a 1.5-time decrease in 
comparison with reference drug Mexidol 85.72 mg/kg/day.
Thus, 3-oxypiridine derivative LHT 21–16 led to a de-
crease in the necrosis level under conditions of 30 min-
utes of ischemia followed by 90 minutes of reperfusion 
in rabbits, which was expressed in a decreasd size of the 
necrotic zone and a reduced level of Tn I, a biochemical 
marker of myocardial damage. It was shown in the exper-
iment that LHT 21–16 reduces the necrotic zone 1.9 times 
in comparison with the control. In addition, LHT 21–16 
limited an increase in myocardial damage marker Tn I, 
like Mexidol, but surpassing it 1.5 times in efficiency.
At the beginning of prolonged ischemia, two separate 
pathological processes occur. The first process is tissue 
damage caused by ischemia as such. The second is the 
biochemical changes that occur during ischemia and 
contribute to the surge in generating ROS and infiltrat-
ing pro-inflammatory neutrophils and other immuno-
cytes when molecular oxygen is re-introduced into tis-
sues during reperfusion (Popelova et al. 2008). Despite 
the fact that reperfusion restores the delivery of oxygen 
and substrates necessary for the generation of aerobic 
ATP, and normalizes the extracellular pH, the effect of 
re-oxygenation disrupts the process of oxygen reduction 
in the ischemic myocardium, which leads to the accumu-
lation of significant amounts of the ROS (Kotlyarov and 
Smirnov 2004). It inevitably leads to the activation of the 
lipid peroxidation (LPO) (Štěrba et al. 2013). LPO acti-
vation has a number of adverse consequences for cardio-
myocytes caused by: postischemic myocardial hyperoxia 
and an influx of pro-oxidants, increased activity of mem-
brane-bound and solubilized phospholipases, as well as to 
the destructive action of the resulting amphiphilic com-
pounds (free fatty acids, lysophospholipids, LPO prod-
ucts) introduced into the lipid bilayer of membranes; the 
stretching and rupture of the sarcolemma and the mem-
brane of the cell organelles due to the accumulation of 
cations in them, in Na+, Ca2+, and, as a consequence – liq-
uid (Zhao et al. 2015). Since ROS is considered to be one 
of the main factors triggering the mechanism of death in 
ischemic/reperfusion myocardial damage, the prevention 
of the synthesis of ROSs or their neutralization is obvi-
ously crucial for the survival or recovery of cardiomyo-
cyte function (Pourkhalili et al. 2009). The pharmacologi-
cal group used for this purpose is antioxidants. This group 
includes drugs of different nature and mechanisms of ac-
tion, which ultimately affect the processes of free radical 
oxidation of cell structures and biomolecules, primarily, 
peroxidation of membrane phospholipids (McClements 
and Decker 2018).
Mexidol is one of the 3-hydroxypyridine derivatives, 
which is a universal drug of antioxidant pharmacothera-
py, as it affects the different stages of the oxidative stress: 
inhibits free-radical oxidation of membrane lipids; reacts 
with peroxide radicals of lipids, primary and hydroxyl 
radicals of peptides; reduces the level of NO, increases 
the activity of superoxide dismutase and other antioxidant 
enzymes. Due to its mechanism of action, Mexidol has 
a wide range of pharmacological effects, implemented at 
least at two levels – neuronal and vascular (Volchegorskii 
et al. 2014).
Thus, the group of 3-oxypyridine derivatives contin-
ues to be replenished with new compounds in order to 
improve the pharmacological properties of the mole-
cule. The previous studies have proved that a number of 
3-oxypyridine derivatives have a pronounced antihypox-
ic, anti-ischemic, neuroprotective, endothelioprotective 
properties. However, in order to expand the spectrum of 
action and to improve the efficacy, new compositions with 
different chemical groups are being created.
The prerequisites for the high efficacy of the compound 
may be the presence of privileged chemical groups, in 
particular, hydroxyl, capable of increasing the lipophilic-
Table 1. Impact of compound LHT 21-16, Mexidol on the size of myocardial necrotic zones and troponin I content in blood plasma 
under conditions of ischemia/reperfusion (M±m)
N Group Size of the necrotic zone % The level of Troponin I (ng/ml )
1. Sham operated animals n = 8 0.00±0.00 3.4±1.1*
2. Ischemia/reperfusion, Control n = 8 46.3±5.1# 16.6±2.4#*
3. Ischemia/reperfusion + LHT 21–16 (26.0 mg/kg/day) n = 8 26.2±2.7#* 7.5±1.2#*
4. Ischemia/reperfusion + Mexidol (85.72 mg/kg) n = 8 31.2±3.9#* 11.3±1.7#*
Note: the differences were statistically significant (p<0.05); # – in comparison with group of sham operated animals; * – in comparison with group of 
“ischemia/reperfusion”. All the test compounds were administered once intravenously 30 minutes before reperfusion.
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ity and anti-radical activity of the compound. Using 1H 
NMR, it was found that compound of LHT 21–16 at posi-
tion 3 of the pyridine nucleus has such a group.
Further, to test the high efficacy of lead compound 
LHT 21–16 (52 mg/kg), an evaluation of its cardioprotec-
tive activity was performed when modeling a 30-minute 
coronary occlusion followed by a 90-minute reperfusion, 
where it was shown that a 3-oxypyridine derivative LHT 
21–16 (52 mg/kg) had a cardioprotective effect reducing 
the severity of myocardial ischemic damage, as evidenced 
by a decreased necrotic zone and Tn I level.
In this regard, it is worth continuing search for poten-
tial cardiotropic agents in the group of 3-oxypyridine de-
rivatives.
Conclusions
1. By intensity of the antihypoxic effect, lead-compound 
LHT 21–16 from the group of 3-oxypyrine derivatives 
in in vitro conditions is superior to reference drugs Tri-
metazidine and Mexidol.
2. The physico-chemical method of NMR spectroscopy 
confirmed the chemical structure of lead compound 
LHT 21–16.
3. LHT 21–16 (52 mg/kg) have a cardioprotective effect 
on the model of coronary-occlusive myocardial infarc-
tion, as evidenced by a decreased necrotic zone and 
level of Tn I. The data obtained on the pharmacological 
activity of test compound LHT 21–16 allows recom-
mending it for further in-depth study.
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